[go: up one dir, main page]

WO2008113364A3 - Prévention de la néphrotoxicité iii - Google Patents

Prévention de la néphrotoxicité iii Download PDF

Info

Publication number
WO2008113364A3
WO2008113364A3 PCT/DK2008/050070 DK2008050070W WO2008113364A3 WO 2008113364 A3 WO2008113364 A3 WO 2008113364A3 DK 2008050070 W DK2008050070 W DK 2008050070W WO 2008113364 A3 WO2008113364 A3 WO 2008113364A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
cell
cancer
treatment
amino derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DK2008/050070
Other languages
English (en)
Other versions
WO2008113364A2 (fr
Inventor
Soeren Valdgaard Boye
Jacob Thinggaard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ReceptIcon ApS
Original Assignee
ReceptIcon ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ReceptIcon ApS filed Critical ReceptIcon ApS
Priority to EP08715624A priority Critical patent/EP2139461A2/fr
Publication of WO2008113364A2 publication Critical patent/WO2008113364A2/fr
Publication of WO2008113364A3 publication Critical patent/WO2008113364A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention porte sur l'utilisation de composés pour la fabrication d'un médicament pour la prophylaxie et/ou le traitement d'une toxicité cellulaire induite, telle que la néphrotoxicité et l'ototoxicité, en particulier lorsque la toxicité cellulaire est induite par un traitement médical. Dans un mode de réalisation, les composés ont au moins deux atomes d'azote, et dans un mode préféré, au moins deux groupes amino. Les composés selon l'invention sont capables de bloquer la liaison de composés toxiques pour les cellules au récepteur de la mégaline, et d'inhiber ainsi l'absorption dans les cellules des composés toxiques pour celles-ci. L'invention porte en outre sur de nouveaux composés destinés à être utilisés dans ledit traitement, ainsi que sur un procédé pour réduire la toxicité cellulaire de composés toxiques pour les cellules.
PCT/DK2008/050070 2007-03-20 2008-03-19 Prévention de la néphrotoxicité iii Ceased WO2008113364A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP08715624A EP2139461A2 (fr) 2007-03-20 2008-03-19 Prévention de la néphrotoxicité iii

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200700424 2007-03-20
DKPA200700424 2007-03-20
DKPA200700958 2007-06-29
DKPA200700958 2007-06-29

Publications (2)

Publication Number Publication Date
WO2008113364A2 WO2008113364A2 (fr) 2008-09-25
WO2008113364A3 true WO2008113364A3 (fr) 2009-04-16

Family

ID=39529323

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2008/050070 Ceased WO2008113364A2 (fr) 2007-03-20 2008-03-19 Prévention de la néphrotoxicité iii

Country Status (2)

Country Link
EP (1) EP2139461A2 (fr)
WO (1) WO2008113364A2 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006487B2 (en) 2005-06-15 2015-04-14 Massachusetts Institute Of Technology Amine-containing lipids and uses thereof
US8835506B2 (en) 2008-06-05 2014-09-16 Stc.Unm Methods and related compositions for the treatment of cancer
KR101734955B1 (ko) 2008-11-07 2017-05-12 메사추세츠 인스티튜트 오브 테크놀로지 아미노알콜 리피도이드 및 그의 용도
NZ596186A (en) * 2009-05-05 2014-03-28 Alnylam Pharmaceuticals Inc Lipid compositions
NZ600616A (en) 2009-12-01 2014-11-28 Shire Human Genetic Therapies Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
US9289400B2 (en) * 2010-08-11 2016-03-22 Drexel University D3 dopamine receptor agonists to treat dyskinesia in parkinson's disease
WO2012027675A2 (fr) 2010-08-26 2012-03-01 Massachusetts Institute Of Technology Poly(bêta-amino-alcools), leur préparation et utilisations de ceux-ci
EP2691443B1 (fr) 2011-03-28 2021-02-17 Massachusetts Institute of Technology Lipomères conjugués et utilisations associées
HK1199206A1 (en) 2011-06-08 2015-06-26 夏尔人类遗传性治疗公司 Lipid nanoparticle compositions and methods for mrna delivery
MX363734B (es) 2011-10-27 2019-03-29 Massachusetts Inst Technology Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco.
EP2830603B1 (fr) * 2012-03-28 2018-09-26 University of Central Florida Research Foundation, Inc. Agents thérapeutiques sélectifs en termes de transport des polyamines à stabilité plus élevée
WO2013178763A1 (fr) * 2012-05-30 2013-12-05 Sensorion Procédés pour traiter une vestibulotoxicité
EP2859102A4 (fr) 2012-06-08 2016-05-11 Shire Human Genetic Therapies Polynucléotides résistant à la nucléase et leurs utilisations
WO2014028487A1 (fr) 2012-08-13 2014-02-20 Massachusetts Institute Of Technology Lipidoïdes contenant des amines et leurs utilisations
JP6586075B2 (ja) 2013-03-14 2019-10-02 トランスレイト バイオ， インコーポレイテッド メッセンジャーｒｎａの精製方法
HRP20181580T1 (hr) 2013-03-14 2019-02-22 Translate Bio, Inc. Pripravci cftr irnk i povezani postupci i upotrebe
US9315472B2 (en) 2013-05-01 2016-04-19 Massachusetts Institute Of Technology 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
ES2707966T3 (es) 2013-10-22 2019-04-08 Translate Bio Inc Terapia de ARNm para la deficiencia en síntesis de argininosuccinato
MX2016005239A (es) 2013-10-22 2016-08-12 Shire Human Genetic Therapies Tratamiento con acido ribonucleico mensajero para la fenilcetonuria.
SG11201602943PA (en) 2013-10-22 2016-05-30 Shire Human Genetic Therapies Lipid formulations for delivery of messenger rna
ES2769780T3 (es) 2013-10-28 2020-06-29 Univ Drexel Tratamientos novedosos para los trastornos de atención y cognitivos y para la demencia asociada a un trastorno neurodegenerativo
EP3636742B1 (fr) 2014-04-25 2025-11-05 Translate Bio, Inc. Procédés de purification d'arn messager
JP6557722B2 (ja) 2014-05-30 2019-08-07 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 核酸の送達のための生分解性脂質
UA121863C2 (uk) 2014-06-24 2020-08-10 Транслейт Байо, Інк. Стереохімічно збагачені композиції для доставки нуклеїнових кислот
US9840479B2 (en) 2014-07-02 2017-12-12 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
WO2016205691A1 (fr) 2015-06-19 2016-12-22 Massachusetts Institute Of Technology 2,5-pipérazinediones substituées par un alcényle, et leur utilisation dans des compositions destinées à l'administration d'un agent à un sujet ou une cellule
US10905665B2 (en) 2015-06-24 2021-02-02 Duke University Chemical modulators of signaling pathways and therapeutic use
EP3585417B1 (fr) 2017-02-27 2023-02-22 Translate Bio, Inc. Méthode de préparation d'arnm cftr à codons optimisés
ES2993135T3 (en) 2017-05-16 2024-12-23 Translate Bio Inc Codon-optimized mrna encoding cftr for use in treating cystic fibrosis
CN118421617A (zh) 2018-08-24 2024-08-02 川斯勒佰尔公司 用于纯化信使rna的方法
CA3120647A1 (fr) 2018-11-21 2020-05-28 Translate Bio, Inc. Traitement de la fibrose kystique par administration d'arnm nebulise codant pour la cftr
CN116763804A (zh) * 2023-07-10 2023-09-19 徐州工程学院 胡椒基哌嗪联合奈替米星在制备抗荧光假单胞菌感染药物中的应用

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07118148A (ja) * 1993-10-26 1995-05-09 Tsumura & Co 肝癌予防剤
US5474779A (en) * 1992-03-11 1995-12-12 Bufius; Nataliya Compositions for aiding in the regeneration of tissue with a prolonged immunomodulating effect
WO1998010757A2 (fr) * 1996-09-11 1998-03-19 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Utilisation d'antagonistes fonctionnels du n-methyl-d-aspartate pour reduire ou prevenir l'ototoxicite induite par l'aminoglucoside
US5763569A (en) * 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
WO1999022744A1 (fr) * 1997-11-05 1999-05-14 Geltex Pharmaceuticals, Inc. Reduction du niveau d'oxalates par des polyamines aliphatiques
WO1999051213A2 (fr) * 1998-04-03 1999-10-14 Theodore Toney Ilenchuk Utilisation de polyamines dans le traitement de symptomes dermatologiques
WO2003092668A1 (fr) * 2002-05-02 2003-11-13 Johannes Wohlrab Utilisation d'agmatine pour une application topique
WO2004084799A2 (fr) * 2003-03-27 2004-10-07 Jerachmiel Appelbaum Compositions pharmaceutiques destinees a inhiber l'activite enzymatique dependante des ions metalliques et techniques d'utilisation de celles-ci
WO2004084876A2 (fr) * 2003-03-26 2004-10-07 Recepticon Aps Utilisation de composes pour prevenir la toxicite cellulaire induite par un medicament
US20050085555A1 (en) * 1997-08-21 2005-04-21 Murphy Michael A. Composition, synthesis and therapeutic applications of polyamines
WO2005060569A2 (fr) * 2003-12-11 2005-07-07 Ludwig Institute For Cancer Research Chelateurs a base de tame et utilisations de ceux-ci
WO2006037335A2 (fr) * 2004-10-06 2006-04-13 Recepticon Aps Utilisation de composes pour la prevention d'une toxicite cellulaire induite par un medicament
WO2006040579A1 (fr) * 2004-10-14 2006-04-20 The University Court Of The University Of Glasgow Polymeres bioactifs
WO2006119713A2 (fr) * 2005-05-12 2006-11-16 Centro De Ingenieria Genetica Y Biotecnologia Composes a action antineoplasique et compositions pharmaceutiques les contenant
WO2008107471A2 (fr) * 2007-03-07 2008-09-12 Dextech Medical Ab Conjugués d'hydroxypolymère modifié à activité destructrice de cellules tumorales

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763569A (en) * 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
US5474779A (en) * 1992-03-11 1995-12-12 Bufius; Nataliya Compositions for aiding in the regeneration of tissue with a prolonged immunomodulating effect
JPH07118148A (ja) * 1993-10-26 1995-05-09 Tsumura & Co 肝癌予防剤
WO1998010757A2 (fr) * 1996-09-11 1998-03-19 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Utilisation d'antagonistes fonctionnels du n-methyl-d-aspartate pour reduire ou prevenir l'ototoxicite induite par l'aminoglucoside
US20050085555A1 (en) * 1997-08-21 2005-04-21 Murphy Michael A. Composition, synthesis and therapeutic applications of polyamines
WO1999022744A1 (fr) * 1997-11-05 1999-05-14 Geltex Pharmaceuticals, Inc. Reduction du niveau d'oxalates par des polyamines aliphatiques
WO1999051213A2 (fr) * 1998-04-03 1999-10-14 Theodore Toney Ilenchuk Utilisation de polyamines dans le traitement de symptomes dermatologiques
WO2003092668A1 (fr) * 2002-05-02 2003-11-13 Johannes Wohlrab Utilisation d'agmatine pour une application topique
WO2004084876A2 (fr) * 2003-03-26 2004-10-07 Recepticon Aps Utilisation de composes pour prevenir la toxicite cellulaire induite par un medicament
WO2004084799A2 (fr) * 2003-03-27 2004-10-07 Jerachmiel Appelbaum Compositions pharmaceutiques destinees a inhiber l'activite enzymatique dependante des ions metalliques et techniques d'utilisation de celles-ci
WO2005060569A2 (fr) * 2003-12-11 2005-07-07 Ludwig Institute For Cancer Research Chelateurs a base de tame et utilisations de ceux-ci
WO2006037335A2 (fr) * 2004-10-06 2006-04-13 Recepticon Aps Utilisation de composes pour la prevention d'une toxicite cellulaire induite par un medicament
WO2006040579A1 (fr) * 2004-10-14 2006-04-20 The University Court Of The University Of Glasgow Polymeres bioactifs
WO2006119713A2 (fr) * 2005-05-12 2006-11-16 Centro De Ingenieria Genetica Y Biotecnologia Composes a action antineoplasique et compositions pharmaceutiques les contenant
WO2008107471A2 (fr) * 2007-03-07 2008-09-12 Dextech Medical Ab Conjugués d'hydroxypolymère modifié à activité destructrice de cellules tumorales

Non-Patent Citations (20)

* Cited by examiner, † Cited by third party
Title
BASU, HIRAK S. ET AL: "Correlation between the effects of polyamine analogs on DNA conformation and cell growth", CANCER RESEARCH , 49(20), 5591-7 CODEN: CNREA8; ISSN: 0008-5472, 1989, XP007906534 *
BRANA, M. F. ET AL: "Chromophore-Modified Bis-Naphthalimides: Synthesis and Antitumor Activity of Bis-Dibenz[de,h]isoquinoline-1,3-diones", JOURNAL OF MEDICINAL CHEMISTRY , 40(4), 449-454 CODEN: JMCMAR; ISSN: 0022-2623, 1997, XP007906538 *
CAMPHAUSEN K ET AL: "Evaluation of chelating agents as anti-angiogenic therapy through copper chelation", BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER SCIENCE LTD, GB, vol. 12, no. 19, 1 October 2004 (2004-10-01), pages 5133 - 5140, XP004558891, ISSN: 0968-0896 *
COVASSIN, LAURENCE ET AL: "Synthesis of spermidine and norspermidine dimers as high affinity polyamine transport inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS , 9(12), 1709-1714 CODEN: BMCLE8; ISSN: 0960-894X, 1999, XP002506782 *
COVASSIN, LAURENCE ET AL: "Xylylated dimers of putrescine and polyamines: influence of the polyamine backbone on spermidine transport inhibition", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS , 13(19), 3267-3271 CODEN: BMCLE8; ISSN: 0960-894X, 2003, XP007906533 *
DIMMOCK J ET AL: "Mannich bases of phenolic azobenzenes possessing cytotoxic activity", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 32, no. 7-8, 1 July 1997 (1997-07-01), pages 583 - 594, XP004372794, ISSN: 0223-5234 *
EDWARDS M L ET AL: "POLYAMINE ANALOGUES WITH ANTITUMOR ACTIVITY. POLYAMINE ANALOGUES WITH ANTITUMOR ACTIVITY", JOURNAL OF MEDICINAL CHEMISTRY, US AMERICAN CHEMICAL SOCIETY. WASHINGTON, vol. 33, no. 5, 1 May 1990 (1990-05-01), pages 1369 - 1375, XP000604648, ISSN: 0022-2623 *
LEVINE, SEYMOUR ET AL: "Hypothalamic and medullary lesions caused by an aliphatic triamine unrelated to goldthioglucose", JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY , 41(1), 54-66 CODEN: JNENAD; ISSN: 0022-3069, 1982, XP009109539 *
MUIR C P ET AL: "Nitric oxide attenuates resistance to doxorubicin in three-dimensional aggregates of human breast carcinoma cells", BREAST CANCER RESEARCH AND TREATMENT, KLUWER ACADEMIC PUBLISHERS, BO, vol. 96, no. 2, 1 March 2006 (2006-03-01), pages 169 - 176, XP019274993, ISSN: 1573-7217 *
NG, CHIU YUEN ET AL: "1,4-Bis[2,5,5-tris(carboxymethyl)-2,5-diazapentyl]benzene (PXED3A): synthesis, binuclear chelating tendencies, and iron(III) .mu.-oxo-bridge formation", INORGANIC CHEMISTRY , 22(5), 721-8 CODEN: INOCAJ; ISSN: 0020-1669, 1983, XP007906530 *
OGUCHI, HISAO ET AL: "Effect of lactose derivatives on metastatic potential of B16 melanoma cells", CANCER COMMUNICATIONS , 2(9), 311-16 CODEN: CNCMET; ISSN: 0955-3541, 1990, XP009109561 *
PALMER, BRIAN D. ET AL: "Synthesis, DNA binding interactions and biological activity of bis-platinum (II) complexes of N,N,N',N'-tetrakis(2-aminoethyl)diamines", ANTI-CANCER DRUG DESIGN , 7(5), 385-401 CODEN: ACDDEA; ISSN: 0266-9536, 1992, XP002939720 *
RUSTENBECK I ET AL: "Polyamine modulation of mitochondrial calcium transport. II. Inhibition of mitochondrial permeability transition by aliphatic polyamines but not by aminoglucosides.", BIOCHEMICAL PHARMACOLOGY 15 OCT 1998, vol. 56, no. 8, 15 October 1998 (1998-10-15), pages 987 - 995, XP007906535, ISSN: 0006-2952 *
RUSTENBECK, INGO ET AL: "Polyamine modulation of mitochondrial calcium transport, I. Stimulatory and inhibitory effects of aliphatic polyamines, aminoglycosides and other polyamine analogs on mitochondrial calcium uptake", BIOCHEMICAL PHARMACOLOGY , 56(8), 977-985 CODEN: BCPCA6; ISSN: 0006-2952, 1998, XP007906539 *
SHA, S.-H. ET AL: "Antioxidants attenuate gentamicin-induced free radical formation in vitro and ototoxicity in vivo: D-methionine is a potential protectant", HEARING RESEARCH , 142(1-2), 34-40 CODEN: HERED3; ISSN: 0378-5955, 2000, XP007906532 *
SHAH, NEHA ET AL: "Activation of Nuclear Factor .kappa.B by Polyamines in Breast Cancer Cells", BIOCHEMISTRY , 38(45), 14763-14774 CODEN: BICHAW; ISSN: 0006-2960, 1999, XP007906536 *
SIBERT, JOHN W. ET AL: "Lipophilic derivatives of cyclam as new inhibitors of tumor cell growth", CHEMICAL COMMUNICATIONS (CAMBRIDGE, UNITED KINGDOM) , (2), 154-155 CODEN: CHCOFS; ISSN: 1359-7345, 2002, XP007906537 *
TAKAO K ET AL: "Studies on inhibition of enzymatic arginyltransfer reaction", CHEMICAL AND PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN, TOKYO, vol. 46, no. 7, 1 January 1998 (1998-01-01), pages 1169 - 1172, XP009109711, ISSN: 0009-2363 *
WILLIAMS P D ET AL: "Inhibition of renal membrane binding and nephrotoxicity of aminoglycosides", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, AMERICAN SOCIETY FOR PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, US, vol. 237, no. 3, 1 January 1986 (1986-01-01), pages 919 - 925, XP009109529, ISSN: 0022-3565 *
ZANG, ERLE ET AL: "Synthesis of hexamine ligands by using trityl as an N-blocking group", SYNTHETIC COMMUNICATIONS , 27(18), 3145-3150 CODEN: SYNCAV; ISSN: 0039-7911, 1997, XP009109581 *

Also Published As

Publication number Publication date
EP2139461A2 (fr) 2010-01-06
WO2008113364A2 (fr) 2008-09-25

Similar Documents

Publication Publication Date Title
WO2008113364A3 (fr) Prévention de la néphrotoxicité iii
WO2004084876A3 (fr) Utilisation de composes pour prevenir la toxicite cellulaire induite par un medicament
PH12012502057A1 (en) Compounds for inhibiting mitotic progression
WO2007133637A3 (fr) Dérivés d'amides en tant que ligands de canal ionique et compositions pharmaceutiques et méthodes d'utilisation desdits dérivés
NZ577916A (en) Cyclopamine analogs
WO2008021038A3 (fr) Pyridobenzazépines et méthodes d'inhibition de la progression mitotique
NZ609344A (en) Method for treatment of diarrhea-predominant irritable bowel syndrome
WO2008024978A3 (fr) Dérivés de benzène, de pyridine et de pyridazine
WO2008012532A3 (fr) Composés chimiques 428
WO2007109172A3 (fr) Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 et leurs utilisations
MX2009012155A (es) Combinación farmacéutica sinérgica para el tratamiento de cáncer.
WO2006102610A3 (fr) Composes bicycloheteroaryle utilises en tant que modulateurs de p2x7 et leurs utilisations
WO2007109154A3 (fr) Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 modulators et leurs utilisations
UA105390C2 (ru) МОТИВЫ ХИМИЧЕСКИХ МОДИФИКАЦИЙ ДЛЯ ИНГИБИТОРОВ И МИМЕТИКОВ мкРНК
WO2007113558A8 (fr) Composés chimiques
WO2009026179A3 (fr) Composés de proanthocyanidine anti-infectieux et leurs procédés d'utilisation
MY155695A (en) Quinoxalinedione derivatives
WO2008013987A3 (fr) Pipérazinylméthylquinazolinones et azépanylméthylquinazolinones à substitution n-alkyle
WO2011058027A3 (fr) Composés de purine n-9-substitués, compositions et procédés d'utilisation
WO2007109201A3 (fr) Composés de bicyclohétéroaryle en tant que modulateur de p2x7 et leurs utilisations
AU2007249926A8 (en) Monocyclic heteroaryl compounds
MX2009012523A (es) Composiciones utiles para reducir la nefrotoxicidad y metodos para utilizarlas.
EP2215054B8 (fr) Dérivés amide à titre de ligands des canaux ioniques et compositions pharmaceutiques et procédés d'utilisation correspondants
WO2008002460A3 (fr) Composés antinéoplasiques indépendants de la lumière disponibles sous une forme orale
WO2006037335A3 (fr) Utilisation de composes pour la prevention d'une toxicite cellulaire induite par un medicament

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08715624

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008715624

Country of ref document: EP